However, the 1990s witnessed a dramatic increase in use of GnRH agonists for prostate cancer across all stages and grades [3,4], even though a survival benefit has only been demonstrated in combination with radiation in the subset of patients with locally advanced or high risk disease or following radical prostatectomy in men with node-positive cancer [5-7]. This evidence concerns the gene GNRH1 and Familial prostate cancer.